Efficacy and Safety of Dupilumab Across Different Th2-Type-Mediated Diseases: A Real-Life Preliminary Experience
Background: Dupilumab, a fully human monoclonal antibody targeting the interleukin (IL)-4/IL-13 pathway, is able to dampen T helper (Th)2-mediated inflammation in several conditions characterized by this particular type of phlogosis. The aim of this study was to review the efficacy and safety of dup...
Saved in:
| Main Authors: | Ciro Romano, Domenico Cozzolino, Maria Elena Corona, Ernesto Aitella |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-01-01
|
| Series: | Biologics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-8449/5/1/3 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Chronic pruritus: a narrative review
by: Paulo Ricardo Criado, et al.
Published: (2025-08-01) -
Successful Treatment of Pediatric Atopic Prurigo Nodularis with Dupilumab
by: Zhang Y, et al.
Published: (2025-06-01) -
Four Cases of Prurigo Nodularis Requiring Nemolizumab due to Persistent Pruritus or Lesions after Dupilumab Treatment
by: Yoshihito Mima, et al.
Published: (2025-06-01) -
Case report: Dupilumab-induced linear psoriasis: a rare presentation
by: Wen Sun, et al.
Published: (2025-01-01) -
Long-term effects of dupilumab on chronic rhinosinusitis with nasal polyps: A step towards clinical remission
by: Mona Al-Ahmad, MD, FRCPC, et al.
Published: (2025-02-01)